Mersana Therapeutics (MRSN) Misses Q4 EPS by 28c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Mersana (MRSN) PT Lowered to $11 at Wedbush
March 12, 2019 7:19 AM EDTWedbush analyst David Nierengarten lowered the price target on Mersana (NASDAQ: MRSN) to $11.00 (from $15.00) while maintaining a Outperform rating.
Ph 1b dose escalation data from MRSNs XMT-1536 is expected in 2Q19MRSN set to unveil their next clinical candidate in H2:19... More